JPS6034906A - ジピリダモール経口錠剤 - Google Patents
ジピリダモール経口錠剤Info
- Publication number
- JPS6034906A JPS6034906A JP59070736A JP7073684A JPS6034906A JP S6034906 A JPS6034906 A JP S6034906A JP 59070736 A JP59070736 A JP 59070736A JP 7073684 A JP7073684 A JP 7073684A JP S6034906 A JPS6034906 A JP S6034906A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- tablet
- dipyridamole
- disintegrant
- sodium starch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 title claims description 40
- 229960002768 dipyridamole Drugs 0.000 title claims description 40
- 239000007935 oral tablet Substances 0.000 title claims description 7
- 239000003826 tablet Substances 0.000 claims description 63
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 46
- 239000002253 acid Substances 0.000 claims description 42
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 24
- 239000001530 fumaric acid Substances 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 19
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 16
- 239000008109 sodium starch glycolate Substances 0.000 claims description 16
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 16
- 239000007884 disintegrant Substances 0.000 claims description 14
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 9
- 229960000913 crospovidone Drugs 0.000 claims description 9
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 9
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 8
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 7
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical group CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims description 7
- 229960005168 croscarmellose Drugs 0.000 claims description 7
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 6
- 238000013270 controlled release Methods 0.000 claims description 6
- 231100000252 nontoxic Toxicity 0.000 claims description 6
- 230000003000 nontoxic effect Effects 0.000 claims description 6
- 229940096978 oral tablet Drugs 0.000 claims description 5
- 229940080313 sodium starch Drugs 0.000 claims description 5
- 239000003218 coronary vasodilator agent Substances 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000012953 feeding on blood of other organism Effects 0.000 claims 2
- 229930182470 glycoside Natural products 0.000 claims 2
- 150000002338 glycosides Chemical class 0.000 claims 2
- RWYFURDDADFSHT-RBBHPAOJSA-N diane Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1=C(Cl)C2=CC(=O)[C@@H]3CC3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RWYFURDDADFSHT-RBBHPAOJSA-N 0.000 claims 1
- 239000011872 intimate mixture Substances 0.000 claims 1
- 239000003186 pharmaceutical solution Substances 0.000 claims 1
- 230000000304 vasodilatating effect Effects 0.000 claims 1
- 238000004090 dissolution Methods 0.000 description 21
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
- 235000019359 magnesium stearate Nutrition 0.000 description 9
- 230000002378 acidificating effect Effects 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 3
- 235000011613 Pinus brutia Nutrition 0.000 description 3
- 241000018646 Pinus brutia Species 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000008240 homogeneous mixture Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000004922 lacquer Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- JTNCEQNHURODLX-UHFFFAOYSA-N 2-phenylethanimidamide Chemical compound NC(=N)CC1=CC=CC=C1 JTNCEQNHURODLX-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 229960003403 betaine hydrochloride Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- HOPSCVCBEOCPJZ-UHFFFAOYSA-N carboxymethyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC(O)=O HOPSCVCBEOCPJZ-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- -1 hydrochloric Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000006259 organic additive Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940071117 starch glycolate Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48328583A | 1983-04-08 | 1983-04-08 | |
| US483285 | 1983-04-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6034906A true JPS6034906A (ja) | 1985-02-22 |
| JPH0521892B2 JPH0521892B2 (enExample) | 1993-03-25 |
Family
ID=23919470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59070736A Granted JPS6034906A (ja) | 1983-04-08 | 1984-04-09 | ジピリダモール経口錠剤 |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP0121901B1 (enExample) |
| JP (1) | JPS6034906A (enExample) |
| KR (1) | KR880002139B1 (enExample) |
| AT (1) | ATE32980T1 (enExample) |
| AU (1) | AU570446B2 (enExample) |
| CA (1) | CA1219216A (enExample) |
| DD (1) | DD222496A5 (enExample) |
| DE (1) | DE3469848D1 (enExample) |
| DK (1) | DK166259C (enExample) |
| ES (1) | ES8601687A1 (enExample) |
| FI (1) | FI82604C (enExample) |
| GR (1) | GR81907B (enExample) |
| HU (1) | HU191542B (enExample) |
| IE (1) | IE57220B1 (enExample) |
| IL (1) | IL71458A (enExample) |
| NO (1) | NO164958C (enExample) |
| NZ (1) | NZ207768A (enExample) |
| PH (1) | PH21585A (enExample) |
| PT (1) | PT78380B (enExample) |
| ZA (1) | ZA842562B (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62242615A (ja) * | 1986-04-16 | 1987-10-23 | Fujisawa Pharmaceut Co Ltd | マトリツクス錠 |
| JPH0899906A (ja) * | 1995-01-17 | 1996-04-16 | Chugai Pharmaceut Co Ltd | フマル酸含有徐放性製剤 |
| JP2007502788A (ja) * | 2003-08-16 | 2007-02-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ３−［（２−｛［４−（ヘキシルオキシカルボニルアミノ−イミノ−メチル）−フェニルアミノ］−メチル｝−１−メチル−１ｈ−ベンズイミダゾール−５−カルボニル）−ピリジン−２−イル−アミノ］−プロピオン酸エチルエステルまたはその塩を含む錠剤 |
| JP2009504796A (ja) * | 2005-08-22 | 2009-02-05 | ノバルティス アクチエンゲゼルシャフト | ｐＨ依存性薬剤化合物、ｐＨ調整剤および遅延剤を含む医薬組成物 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5188840A (en) * | 1985-09-26 | 1993-02-23 | Chugai Seiyaku Kabushiki Kaisha | Slow-release pharmaceutical agent |
| BG860Y1 (bg) * | 2004-09-17 | 2007-02-28 | "Софарма" Ад | Лекарствена форма на дипиридамол |
| CA2671470C (en) | 2006-12-13 | 2012-05-01 | F. Hoffmann-La Roche Ag | Powder formulation for valganciclovir |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2336218C3 (de) * | 1973-07-17 | 1985-11-14 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Orale Arzneiform |
| DD146547A5 (de) * | 1978-07-15 | 1981-02-18 | Boehringer Sohn Ingelheim | Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen |
| DE3000979A1 (de) * | 1980-01-12 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue dipyridamol-retardformen und verfahren zu ihrer herstellung |
| DE3124090A1 (de) * | 1981-06-19 | 1983-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale dipyridamolformen |
| JPS5839618A (ja) * | 1981-09-04 | 1983-03-08 | Chugai Pharmaceut Co Ltd | 持続性積層錠剤 |
-
1984
- 1984-04-03 KR KR1019840001834A patent/KR880002139B1/ko not_active Expired
- 1984-04-03 HU HU841328A patent/HU191542B/hu not_active IP Right Cessation
- 1984-04-04 AT AT84103698T patent/ATE32980T1/de not_active IP Right Cessation
- 1984-04-04 EP EP84103698A patent/EP0121901B1/en not_active Expired
- 1984-04-04 DE DE8484103698T patent/DE3469848D1/de not_active Expired
- 1984-04-05 GR GR74334A patent/GR81907B/el unknown
- 1984-04-05 ZA ZA842562A patent/ZA842562B/xx unknown
- 1984-04-06 AU AU26609/84A patent/AU570446B2/en not_active Ceased
- 1984-04-06 DD DD84261735A patent/DD222496A5/de not_active IP Right Cessation
- 1984-04-06 DK DK181084A patent/DK166259C/da not_active IP Right Cessation
- 1984-04-06 FI FI841369A patent/FI82604C/fi not_active IP Right Cessation
- 1984-04-06 NZ NZ207768A patent/NZ207768A/en unknown
- 1984-04-06 PT PT78380A patent/PT78380B/pt unknown
- 1984-04-06 NO NO841372A patent/NO164958C/no not_active IP Right Cessation
- 1984-04-06 IE IE856/84A patent/IE57220B1/en not_active IP Right Cessation
- 1984-04-06 CA CA000451489A patent/CA1219216A/en not_active Expired
- 1984-04-06 ES ES531346A patent/ES8601687A1/es not_active Expired
- 1984-04-06 PH PH30512A patent/PH21585A/en unknown
- 1984-04-06 IL IL71458A patent/IL71458A/xx not_active IP Right Cessation
- 1984-04-09 JP JP59070736A patent/JPS6034906A/ja active Granted
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62242615A (ja) * | 1986-04-16 | 1987-10-23 | Fujisawa Pharmaceut Co Ltd | マトリツクス錠 |
| JPH0899906A (ja) * | 1995-01-17 | 1996-04-16 | Chugai Pharmaceut Co Ltd | フマル酸含有徐放性製剤 |
| JP2007502788A (ja) * | 2003-08-16 | 2007-02-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ３−［（２−｛［４−（ヘキシルオキシカルボニルアミノ−イミノ−メチル）−フェニルアミノ］−メチル｝−１−メチル−１ｈ−ベンズイミダゾール−５−カルボニル）−ピリジン−２−イル−アミノ］−プロピオン酸エチルエステルまたはその塩を含む錠剤 |
| JP2009504796A (ja) * | 2005-08-22 | 2009-02-05 | ノバルティス アクチエンゲゼルシャフト | ｐＨ依存性薬剤化合物、ｐＨ調整剤および遅延剤を含む医薬組成物 |
| JP2013136637A (ja) * | 2005-08-22 | 2013-07-11 | Novartis Ag | ｐＨ依存性薬剤化合物、ｐＨ調整剤および遅延剤を含む医薬組成物 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0248447B1 (en) | Sustained release formulations | |
| AU760006B2 (en) | Method for making granules with masked taste and instant release of the active particle | |
| JP2608183B2 (ja) | ピモベンダン経口投与製剤 | |
| CN101237858B (zh) | 胃滞留制剂及其制备方法 | |
| JPH10147517A (ja) | 高められた崩壊特性を有するフイルムコーテイングされた錠剤組成物 | |
| JPH0669965B2 (ja) | 固体持続放出医薬製剤 | |
| WO2003015745A1 (en) | Expandable gastric retention device | |
| JPWO1997033574A1 (ja) | バルプロ酸金属塩の徐放性錠剤 | |
| JP2016514677A (ja) | 硫酸塩の両用経口薬学的組成物錠剤およびその使用の方法 | |
| US4601895A (en) | Delayed-action acetylsalicylic acid formulations for oral administration | |
| JPS6034906A (ja) | ジピリダモール経口錠剤 | |
| US3764668A (en) | Compositions of salts of salicylamide | |
| JP2814513B2 (ja) | 溶出性の改良された製剤組成物 | |
| JP3836893B2 (ja) | ポリカルボフィルカルシウム含有製剤 | |
| JP2003300872A (ja) | 被覆固形催眠製剤 | |
| JP3122478B2 (ja) | 下部消化管放出型経口製剤 | |
| KR0171413B1 (ko) | 젬피브로질 제제 | |
| JP2008081448A (ja) | 酒石酸ゾルピデムの苦味マスキング速放性粒子 | |
| JPH04230216A (ja) | ジェムフィブロジル組成物 | |
| JP2003104896A (ja) | アセチルサリチル酸含有口中崩壊性固形製剤 | |
| WO2003075918A1 (fr) | Comprime contenant du chlorhydrate de pilsicainide (voie humide) | |
| JP2007015966A (ja) | 口腔内崩壊錠 | |
| JPS63243036A (ja) | 持続性固形剤 | |
| AU2002225872A1 (en) | Expandable gastric retention device | |
| JPH11310525A (ja) | グリチルリチン酸含有の重質顆粒 |